Corvus Pharmaceuticals Inc Total Liabilities
Corvus Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has total liabilities worth $13.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CRVS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Corvus Pharmaceuticals Inc (2014–2025)
Total liabilities of Corvus Pharmaceuticals Inc from 2014 to 2025. This chart illustrates how Corvus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Corvus Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Corvus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GL Events SA
PA:GLO
|
France | €2.57 Billion |
|
Hengtong Logistic Co Ltd
SHG:603223
|
China | CN¥1.19 Billion |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
India | Rs-22.18 Billion |
|
Beijing eGOVA
SHE:300075
|
China | CN¥612.11 Million |
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥4.14 Billion |
|
MBK Public Company Limited
BK:MBK
|
Thailand | ฿36.21 Billion |
|
Ryerson Holding Corp
NYSE:RYI
|
USA | $1.64 Billion |
|
Direcional Engenharia S.A.
SA:DIRR3
|
Brazil | R$9.70 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Corvus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CRVS total asset value.
Liquidity & Leverage Metrics
Corvus Pharmaceuticals Inc Total Liabilities Ratios Explained
Corvus Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corvus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual total liabilities of Corvus Pharmaceuticals Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.91 Million | -72.72% |
| 2024-12-31 | $36.34 Million | +429.03% |
| 2023-12-31 | $6.87 Million | -43.35% |
| 2022-12-31 | $12.12 Million | -1.37% |
| 2021-12-31 | $12.29 Million | -8.13% |
| 2020-12-31 | $13.38 Million | +6.75% |
| 2019-12-31 | $12.54 Million | +58.75% |
| 2018-12-31 | $7.90 Million | -20.56% |
| 2017-12-31 | $9.94 Million | +35.26% |
| 2016-12-31 | $7.35 Million | -94.33% |
| 2015-12-31 | $129.56 Million | +921.12% |
| 2014-12-31 | $12.69 Million | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more